Tillkännagivande • May 18

Gsk plc Receives Expanded Approval in Japan for Adults Aged 18-59 At Increased Risk

GSK plc announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has expanded the eligible population for Arexvy (Respiratory Syncytial Virus vaccine, [adjuvanted, recombinant]), to include adults aged 18 to 49 years at increased risk (AIR) for RSV disease. GSK's RSV vaccine was previously approved in Japan for the prevention of RSV disease in all adults aged 60 years and older, and for adults aged 50-59 AIR for RSV disease. The prescribing information for Arexvy has also been updated to explicitly include immuno-compromised (IC) patients as an increased risk group - helping clinicians to identify people who may benefit from RSV prevention. RSV is a common and contagious respiratory virus that can cause serious illness in adults, particularly those living with certain chronic conditions. RSV infection can cause major adverse cardiovascular events (MACE) including heart attack and stroke, trigger flare-ups of chronic obstructive pulmonary disease (COPD) and asthma and may result in severe illness, hospitalisation, and even death. More than 42 million adults in Japan are aged 18-49 and, while often considered at low risk of RSV, many in this group live with underlying chronic conditions. The approval was supported by data from a Phase IIIb trial (NCT06389487) demonstrating a non-inferior immune response in adults aged 18 to 49 years AIR for RSV disease compared to adults aged 60 years and above. Vaccine efficacy was demonstrated in the earlier Phase III trial (NCT04886596). The safety profile was consistent with findings from the broader Phase III programme that supported the initial approval with the most common adverse events being injection site pain, myalgia, fatigue, arthralgia and headache, which were largely transient and mild to moderate in intensity. The update to the prescribing information to include IC patients, accepted by Japan's Pharmaceuticals and Medical Devices Agency (PMDA), was supported by data from a Phase IIb trial (NCT05921903). GSK continues to advance regulatory submissions for its RSV vaccine across multiple geographies to expand availability and support disease prevention. Respiratory Syncytial Virus vaccine (adjuvanted) contains recombinant RSV glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined with GSK's proprietary AS01E adjuvant before administration. The use of this vaccine should be in accordance with official recommendations. As with any vaccine, a protective immune response may not be elicited in all vaccinees. The vaccine has been approved for the prevention of RSV-LRTD in individuals 60 years of age and older in 70 countries. In addition, it is approved for use in individuals aged 50-59 years who are at increased risk due to certain underlying medical conditions in more than 60 countries. In the US it is also approved in adults aged 18-49 years at increased risk, and in the European Economic Area for all adults aged 18 years and older. The GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of Agenus Inc. STIMULON is a trademark of SaponiQx Inc., a subsidiary of Agenus. Please refer to the updated Product Information (PI) for precautions concerning indications, dosage and administration and safety information in Japan. NCT06389487 is a Phase IIIb, open-label multi-country immunogenicity trial to evaluate the non-inferiority of the immune response and evaluate safety in participants aged 18-49 at increased risk for lower respiratory tract disease (LRTD) caused by RSV (n=1,029), compared to participants aged 60 years and above (n=429) after a single dose of GSK's RSV vaccine. Of the 18-49 cohort, 426 were included in the immunogenicity analysis and 603 were assessed for safety only. A total of 1,458 participants were enrolled across 52 locations in six countries, including four sites in Japan. The trial's primary endpoints were RSV-A and RSV-B neutralisation titres expressed as mean geometric titre ratio (relative to older adults over adults at increased risk) and sero-response rate in RSV-A and RSV-B neutralising titres one month post vaccine administration. There were also safety and immunogenicity secondary and tertiary endpoints. NCT04886596 is a Phase III, randomised, placebo-controlled, observer-blind, multi-country trial to evaluate vaccine efficacy of a single dose, and annual revaccination doses of GSK's RSV vaccine, in preventing RSV-LRTD in adults aged 60 years and above. A total of 26,675 participants were enrolled across 277 locations in 17 countries, including 14 sites in Japan. The trial's primary endpoint was vaccine efficacy against RSV-LRTD after one RSV season following a single dose of the vaccine. There were also efficacy, safety and immunogenicity secondary and tertiary endpoints. NCT05921903 is a Phase IIb, open-label, multi-country, descriptive immunogenicity and safety trial in IC participants who were recipients of lung or kidney transplant, and aged 18 years and above at increased risk for severe lower respiratory tract disease (LRTD) caused by RSV (n=261). The trial compared one (n=131) versus two (n=130) doses of GSK's RSV vaccine in IC and AIR participants, and also compared to a control group of non-immunocompromised adults aged 50 and above receiving a single dose (n=125). A total of 386 participants were enrolled across 46 locations in eight countries, including eight sites in Japan. The trial's co-primary endpoints were RSV-A and RSV-B neutralisation titres following a first and a second dose of GSK's RSV vaccine, measured at approximatively one month (30-42 days) after the respective vaccination, expressed as mean geometric increase post dose two relative to post dose one. There were also safety and immunogenicity secondary and tertiary endpoints. The results demonstrated that a single dose of the vaccine showed a robust immune response in the study population. The safety profile was consistent with findings from the broader Phase III programme that supported the initial approval, with the most common adverse events being injection site pain, myalgia, fatigue, arthralgia and headache. RSV is a common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year. Adults can be at increased risk for RSV disease due to certain comorbidities, immune compromised status, or advanced age. RSV can exacerbate certain conditions, including COPD, asthma, and chronic heart failure and can lead to severe outcomes, such as pneumonia, hospitalisation, and death. The true number of RSV-related cases is likely underestimated due to lack of routine testing.

VD-lön i procent	n/a
Anställning som VD	less than a year
Ägande av VD	0.007%
Ledningens genomsnittliga anställningstid	3.5yrs
Styrelsens genomsnittliga mandatperiod	3.8yrs

Namn	Position	Anställning	Kompensation	Ägarskap
Julie Brown	CFO & Executive Director	3.2yrs	UK£9.73m	0.0043% $ 4.3m
Emma Walmsley	Executive Officer	less than a year	UK£15.68m	0% $ 0
Jesse Goodman	Scientific & Medical Expert	no data	UK£61.57k	inga uppgifter
Luke Miels	CEO & Director	less than a year	inga uppgifter	0.0073% $ 7.3m
Shobie Ramakrishnan	Chief Digital & Technology Officer	5.4yrs	inga uppgifter	inga uppgifter
Tony Wood	Chief Scientific Officer and Head of R&D	3.8yrs	inga uppgifter	inga uppgifter
Constantin Fest	Senior VP & Head of Investor Relations	no data	inga uppgifter	inga uppgifter
James Ford	Senior VP and Group General Counsel of Legal & Compliance	7.8yrs	inga uppgifter	inga uppgifter
David Redfern	President of Corporate Development	no data	inga uppgifter	inga uppgifter
Roanne Parry	Chief People Officer	less than a year	inga uppgifter	inga uppgifter
Philip Thomson	President of Global Affairs	9.2yrs	inga uppgifter	0.0084% $ 8.5m
Regis Simard	President of Global Supply Chain	no data	inga uppgifter	inga uppgifter

Namn	Position	Anställning	Kompensation	Ägarskap
Julie Brown	CFO & Executive Director	3.1yrs	UK£9.73m	0.0043% $ 4.3m
Luke Miels	CEO & Director	less than a year	inga uppgifter	0.0073% $ 7.3m
Jonathan Symonds	Chair	6.8yrs	UK£833.00k	0.0023% $ 2.3m
Vishal Sikka	Independent Non-Executive Director	3.9yrs	UK£179.52k	0.00062% $ 627.2k
Hal Barron	Non-Executive Director	8.4yrs	UK£342.73k	0.034% $ 34.2m
Harry Dietz	Independent Non-Executive Director	4.4yrs	UK£210.68k	0.00024% $ 242.8k
Anne Beal	Independent Non-Executive Director	5.1yrs	UK£183.97k	0.00025% $ 252.9k
Wendy Mira Becker	Independent Non-Executive Director	2.7yrs	UK£202.00k	0.00030% $ 303.5k
Charles Bancroft	Senior Independent Non-Executive Director	6.1yrs	UK£262.61k	0.0020% $ 2.1m
Gavin Screaton	Independent Non-Executive Director	1.1yrs	UK£108.00k	0.00038% $ 384.4k
Tsun-Huei Lee	Independent Non-Executive Director	2.3yrs	UK£166.17k	0.000090% $ 91.0k
Elizabeth Anderson	Independent Non-Executive Director	3.8yrs	UK£148.37k	0.00017% $ 172.0k

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/06/01 20:35
Aktiekurs vid dagens slut	2026/05/29 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

Analytiker	Institution
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
Emily Field	Barclays

GSK Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Senaste uppdateringar av ledningen

GSK plc, Annual General Meeting, May 06, 2026

GSK plc Appoints Elizabeth McKee Anderson as Member of the Corporate Responsibility Committee, Effective March 9, 2026

GSK plc Appoints Luke Victor Miels as Director, Effective January 1, 2026

GSK plc, Annual General Meeting, May 07, 2025

GSK plc Announces Board and Committee Changes

Recent updates

Sino Biopharmaceutical Limited Presents Data From Two Phase III Clinical Trials Of Bepirovirsen At EASL 2026

GSK PLC Reports Positive Phase 3 Data For Bepirovirsen In Chronic Hepatitis B

GSK plc to Report Q3, 2026 Results on Oct 28, 2026

Gsk plc Receives Expanded Approval in Japan for Adults Aged 18-59 At Increased Risk

GSK plc Announces Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA

Gsk plc Receives US FDA Breakthrough Therapy and Ema Priority Medicines (Prime) Designations for Mash

GSK plc to Report Q1, 2026 Results on Apr 29, 2026

GSK plc Announces the National Medical Products Administration of China Has Approved Blenrep (Belantamab Mafodotin) in Combination with Bortezomib and Dexamethasone (BVd) for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma

GSK plc Receives Additional Marketing Approval for Depemokimab

GSK plc (LSE:GSK) completed the acquisition of 35Pharma Inc.

Bioversys Ag Publishes Pre-Clinical Data of Alpe Drug Combination in Nature Communications

GSK plc Announces Exdensur Approval for CRSwNP in China

Samsung Biologics America, Inc completed the acquisition of Human Genome Sciences Inc. from GSK plc (LSE:GSK).

Bepirovirsen Accepted for Regulatory Review in China as A Potential First-In-Class Functional Cure for Chronic Hepatitis B

GSK PLC Bepirovirsen Accepted For Review By The European Medicines Agency As A Potential First-In-Class Treatment For Chronic Hepatitis B

GSK plc, Annual General Meeting, May 06, 2026

US Food and Drug Administration Approves GSK plc's Lynavoy(linerixibat)

GSK plc Announces Expansion of AREXVY Approval to Adults Aged 18 to 49 Years for RSV Prevention

Angeion Group Announces Proposed Settlement in DeCostanzo v. GlaxoSmithKline

GSK plc Appoints Elizabeth McKee Anderson as Member of the Corporate Responsibility Committee, Effective March 9, 2026

GSK plc (LSE:GSK) completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc Announces That Japan's Ministry of Health, Labour and Welfare Accepts for Review A New Drug Application for Bepirovirsen

GSK plc (LSE:GSK) entered an agreement to acquire 35Pharma Inc for CAD 950 million.

GSK plc Announces New Effectiveness Data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) At RSVVW'26

GSK plc's RSV Vaccine Accepts for Review by China's Center for Drug Evaluation for the Prevention of Lower Respiratory Syncytial Virus Disease

GSK plc Announces Nucala (Mepolizumab) Approval by European Commission for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Gsk Plc's Rsv Vaccine Receives European Approval for Expanded Use in All Adults 18 Years and Older

GSK plc (LSE:GSK) entered a definitive agreement to acquire RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc to Report Q4, 2025 Results on Feb 04, 2026

GSK plc Appoints Luke Victor Miels as Director, Effective January 1, 2026

GSK plc Announces Positive Topline Results from B-Well 1 and B-Well 2 Phase 3 Studies for Bepirovirsen

GSK plc Announces the Approval of Exdensur ( Depemokimab) by Japan's Ministry of Health, Labour and Welfare

GSK plc Announces China's National Medical Products Administration Approval of Nucala (Mepolizumab) as Add-On Maintenance Treatment of Adult Patients with Inadequately Controlled COPD

Samsung Biologics America, Inc. entered into a definitive agreement to acquire Human Genome Sciences Inc. from GSK plc (LSE:GSK) for $280 million.

Spero Therapeutics, Inc. Announces Nda Resubmission of Tebipenem Hbr by Gsk to the Fda for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

GSK plc Announces Exdensur (depemokimab) Approved by US FDA for the Treatment of Severe Asthma

GSK plc Announces the Marketing Authorisation of Exdensur ( Depemokimab) by the UK's Medicines and Healthcare Products Regulatory Agency

GSK plc Announces US FDA Approval Of Blujepa For Gonorrhoea Indication

GSK plc Receives Orphan Drug Designation from US Food and Drug Administration for the Treatment of Small-Cell Lung Cancer

GSK plc Upgrades Earnings Guidance for the Year Ending December 31, 2025

GSK plc Announces US FDA Approves Blenrep (Belantamab Mafodotin-Blmf) in Combination with Bortezomib and Dexamethasone (BVd) for Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

GSK plc Announces Positive Phase III Data for Next-Generation Low Carbon Version of Ventolin Metered Dose Inhaler

GSK's Shingrix New Prefilled Syringe Presentation Receives Positive CHMP Opinion

GSK's Shingrix Approved in China for Prevention of Shingles in Adults Aged 18 and over Who are at Increased Risk Due to Immunodeficiency or Immunosuppression

GSK plc to Report Q3, 2025 Results on Oct 29, 2025

GSK plc Announces Major Update to Vaccine Track

US Food and Drug Administration Accepts GSK plc's Gepotidacin as an Oral Option for the Treatment of Unplicated Urogenital Grogenital Grogenital Gonorrhoea

GSK plc Provides Update on US Settlement of CureVac/BioNTech mRNA Patent litigation

GSK plc Declares Second Interim Dividend for Second Quarter of 2025, Payable on 9 October 2025

GSK plc Announces Blenrep (Belantamab Mafodotin) Combinations Approved in EU for Treatment of Relapsed/Refractory Multiple Myeloma

GSK plc Provides Update on US FDA Advisory Committee Review of Blenrep (belantamab Mafodotin-blmf) Combinations

US FDA Accepts Application to Review Expanded Use of GSK's RSV Vaccine, Arexvy, for Adults 18-49 At Increased Risk

GSK plc (LSE:GSK) completed the acquisition of Efimosfermin alfa drug from Boston Pharmaceuticals Inc.

GSK plc Announces FDA Approves Benlysta (belimumab) Autoinjector for Children with Active Lupus Nephritis

Gsk plc Announces Japan's Ministry of Health, Labour and Welfare Accepts Regulatory Application to Expand Use of Gsk's Rsv Vaccine

GSK plc Announces the Linked by Lupus: Optimal Care Initiative to Help Support Individuals with Lupus in the US

GSK plc's RSV Vaccine Accepts for Regulatory Review by the European Medicines Agency to Expand Use in Adults 18 Years and Older

GSK plc announces the US Food and Drug Administration has accepted for review the NDA for linerixibat

GSK plc and Spero Therapeutics Announces PIVOT-PO Phase III Study for Tebipenem HBr Starts Early for Efficacy

GSK plc Announces Blenrep (Belantamab Mafodotin) Combination Receive Positive CHMP Opinion in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Approval Ofenrep Combinations by Japan's Ministry of Health, Labour and Welfare for the Treatment of Adults with Relapsed/Refractory Multiple Myeloma

GSK plc (LSE:GSK) agreed to acquire Efimosfermin alfa drug from Boston Pharmaceuticals Inc. for $2 billion.

GSK plc Announces Positive Results for Nucala

GSK plc Announces the Authorisation of Blenrep by the Medicines and Healthcare Products Regulatory Agency

GSK plc Recommends the Use of RSV Vaccines Including GSK'sAREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)

GSK plc to Report Q1, 2025 Results on Apr 30, 2025

GSK's Omjjara (Momelotinib) Approves in Singapore as the First Treatment Indicated for Myelofibrosis Patients with Anaemia

GSK plc, Annual General Meeting, May 07, 2025

US Food and Drug Administration Accepts Depemokimab Application for the Use of D Epemokimab in Two Indications

GSK plc (LSE:GSK) announces an Equity Buyback for £2,000 million worth of its shares.